CUSIP: 14740B606
Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
40,606,477
-
Share change
-
+26,331,597
-
Total reported value
-
$168,106,691
-
Put/Call ratio
-
0%
-
Price per share
-
$4.14
-
Number of holders
-
67
-
Value change
-
+$109,037,876
-
Number of buys
-
52
-
Number of sells
-
10
Quarterly Holders Quick Answers
What is CUSIP 14740B606?
CUSIP 14740B606 identifies CASC - CASCADIAN THERAPEUTICS INC - COM NEW in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2017
-
Previous quarter:
Q4 2016
Recent filing periods for CUSIP 14740B606:
Institutional Holders of CASCADIAN THERAPEUTICS INC - COM NEW (CASC) as of Q1 2017
As of 31 Mar 2017,
CASCADIAN THERAPEUTICS INC - COM NEW (CASC) was held by
67 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
40,606,477 shares.
The largest 10 holders included
NEA Management Company, LLC, BAUPOST GROUP LLC/MA, Redmile Group, LLC, BVF INC/IL, EcoR1 Capital, LLC, venBio Select Advisor LLC, VANGUARD GROUP INC, FRANKLIN RESOURCES INC, Abingworth LLP, and QVT Financial LP.
This page lists
67
institutional shareholders reporting positions in this security
for the Q1 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.